Satsuma Pharmaceuticals, Inc. Common Stock (STSA)

STSA was delisted on the 7th of June, 2023.

• Market cap: $36.5M
• Sector: Healthcare
• Industry: Drug Manufacturers - General

About: Satsuma Pharmaceuticals Inc is a clinical-stage biopharmaceutical company engaged in developing a novel therapeutic product for the treatment of migraine. Its product candidate, STS101, is a drug-device combination of a dry-powder formulation of dihydroergotamine mesylate, or DHE, which can be self-administered with a pre-filled, single-use, nasal delivery device.

Employees: 25